evipedia.ai
← Back

Sermorelin for Health & Longevity

Evidence Review created on 10/26/2026 using AI4L / Opus 5.5

Also known as: Sermorelin Acetate, Geref, Geref Diagnostic, GRF 1-29, GHRH(1-29)NH2, GHRH 1-29

Motivation

Sermorelin (sermorelin acetate) is a laboratory-made copy of the first 29 building blocks of the brain’s own signal for releasing growth hormone. Injected under the skin each evening, it prompts the pituitary gland to release more of the body’s own growth hormone instead of supplying the hormone directly. Because growth hormone output falls steadily with age, sermorelin has drawn interest as a gentler way to bring hormone levels closer to those of younger adults.

Sermorelin was once an approved prescription drug for children who grew too slowly, and its maker later stopped selling it for commercial reasons. Today it is custom-mixed by specialty pharmacies and prescribed by longevity and hormone clinics, often as an alternative to growth hormone itself. University research groups tested nightly injections in healthy older adults during the 1990s and 2000s, looking at body composition and thinking.

This review examines what is known about sermorelin for adults who want to stay healthy and capable as they age: the expected benefits, the risks, how it is used in practice, and how its effects can be tracked.

Benefits - Risks - Protocol - Conclusion

These five items discuss sermorelin, a synthetic fragment of growth hormone-releasing hormone (GHRH, the brain signal that tells the pituitary gland to release growth hormone, GH), in depth from clinical, research and public-health perspectives.

Rhonda Patrick’s FoundMyFitness covers sermorelin publicly only as a brief sleep anecdote in an Andrew Huberman interview (FoundMyFitness Huberman clip), already represented above, and otherwise in a member-only episode, so she is not listed; no relevant content was found from Chris Kresser, Life Extension or Lifespan.io.

Grokipedia

Sermorelin

An AI-written encyclopedia overview of sermorelin’s structure, approval history and pharmacokinetics; its statements on adult benefits and dosing lean on clinic sources and need checking against the trials below.

Examine

No Examine article on sermorelin exists. Examine.com does not typically cover prescription medications, and sermorelin is a prescription-only peptide hormone.

ConsumerLab

No ConsumerLab article on sermorelin exists. ConsumerLab does not typically cover prescription medications such as compounded peptide injections.

Systematic Reviews

No systematic review has examined sermorelin alone; the four reviews below cover GHRH and related growth hormone-releasing agents as a class.

No systematic review or meta-analysis addresses sermorelin’s own risks; the tesamorelin review covers class-level GH-related adverse effects, while cancer risk and long-term safety remain unrepresented in this section.

Mechanism of Action

Sermorelin is the first 29 amino acids of human GHRH, the shortest fragment with full activity (Prakash 1999). It binds the GHRH receptor (GHRHR) on somatotrophs (GH-producing pituitary cells), raising cyclic AMP (cAMP, an internal cell messenger) to trigger GH release and synthesis. GH then drives production of IGF-1 (insulin-like growth factor 1, the mainly liver-made hormone that carries much of GH’s effect). Because somatostatin (the brain’s GH brake) and IGF-1 feedback stay intact, GH release remains pulsed and self-limiting, the core argument of advocates such as Walker, whose research society offered sermorelin free to practitioners (Walker 2006).

Key properties, from the manufacturer’s (Serono) prescribing information (Geref label, reproduced by WorldHealth.net of the “American Academy of Anti-Aging Medicine”, whose members sell hormone therapies):

  • Half-life: 11–12 minutes; levels peak 5–20 minutes after subcutaneous (under the skin) injection.
  • Distribution: about 6% bioavailable under the skin; volume of distribution 24–26 L.
  • Selectivity: pituitary GHRHR; small rises in prolactin (a milk hormone) and gonadotropins (hormones driving testes and ovaries) are reported (reviewed by Sinha 2020).
  • Metabolism: cleaved in blood by DPP-4 (dipeptidyl peptidase-4, an enzyme that clips peptide hormones) and trypsin-like enzymes (Frohman 1989); no liver cytochrome P450 (CYP, drug-metabolizing enzyme) role is known.

A competing view holds that lower GH signaling favors longevity: mice lacking GHRH live longer (Sun 2013), and Brazilians with a GHRHR mutation reach normal or extreme ages with less cancer, per a review (Aguiar-Oliveira 2019).

Historical Context & Evolution

GHRH was isolated in 1982 from pancreatic tumors that caused acromegaly (overgrowth from excess GH) (Guillemin 1982), and was soon tested in adults with childhood-onset GH deficiency (Borges 1983). Serono developed the 29-amino-acid fragment as Geref, which the FDA approved in 1990 for diagnostic testing and in 1997 for children with idiopathic (unexplained) GH deficiency (FDA Federal Register notice). Unable to compete with recombinant (genetically engineered) GH, which a drug review found grew children faster (Prakash 1999), Geref was discontinued in 2008; approval was withdrawn in 2009, and the FDA later determined this was not for safety or effectiveness reasons (FDA Federal Register notice).

Interest in ageing came from the “somatopause”: GH secretion falls steeply with age while the pituitary stays responsive to GHRH. A 1991 National Institute on Aging initiative funded the University of Washington GHRH trial, and groups at the National Institute on Aging, Johns Hopkins and the University of California San Diego also gave GHRH or its fragments to older adults (Corpas 1992; Vittone 1997; Khorram 1997). A review reports that this work raised GH and IGF-1, modestly changed body composition and showed a cognitive signal, but no consistent strength gain (Hersch 2008).

From the mid-2000s, longevity clinics and compounding pharmacies adopted sermorelin, promoted in part by advocates who offered it free to practitioners (Walker 2006). Academic research meanwhile moved to tesamorelin, a stabilized analogue (Baker 2012), and animal and human genetic findings linking lower GH signaling to longer life added a counter-argument that remains unresolved.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the controlled trials of a clinical endpoint each come from a single research group (one randomized pediatric growth trial, one adult cognition trial), and the remaining evidence is uncontrolled series, analogue studies or hormone markers.

Medium 🟩 🟩

Linear Growth in Children With Growth Hormone Deficiency ⭕️ Not Central to Health & Longevity

Sermorelin’s approved indication was unexplained GH deficiency in prepubertal children; it bears on childhood growth, not on adult health or longevity. In the manufacturer-sponsored, uncontrolled Geref International Study Group trial (Thorner) of 110 children, a bedtime dose of 30 µg/kg raised height velocity by about three-quarters (Thorner 1996). The only controlled comparison, a randomized Turkish trial (Neyzi), found high-dose sermorelin matched GH while low-dose fell short (Neyzi 1993). Responses waned in some children, who were switched to GH.

Magnitude: Height velocity rose from 4.1 to 7.2 cm per year after 12 months of treatment (no control group) (Thorner 1996).

Cognitive Performance in Healthy Older Adults

In a placebo-controlled trial of 89 healthy adults (average age 68) by the University of Washington group (Vitiello), six months of nightly sermorelin improved fluid-intelligence tasks (reasoning and processing speed), including performance IQ, picture arrangement and dual-tasking, regardless of sex or estrogen use (Vitiello 2006). The proposed route is IGF-1 acting on memory and planning circuits. The same group saw a benefit with tesamorelin (Baker 2012), but two other tesamorelin trials found no change (Stewart 2026; NCT02572323); none tested sermorelin.

Magnitude: In an interim analysis of 64 participants, sermorelin recipients performed 5–7% better than placebo recipients on processing-speed tasks (Vitiello 2001); the final report gives significance levels without effect sizes.

Low 🟩

Lean Mass and Body Fat ⚠️ Conflicted

Preliminary University of Washington data reported less body fat with a matching lean-mass gain (Vitiello 2001). A one-amino-acid analogue raised lean mass in men only (Khorram 1997), indirect evidence. Six weeks of nightly sermorelin changed neither (Vittone 1997). Net: a modest shift is plausible but unconfirmed.

Magnitude: About 5% lower percent body fat in men and in women not taking oral estrogen after five to six months; within-group change, placebo figure not reported, not compared between groups (Vitiello 2001).

Muscle Strength and Physical Function ⚠️ Conflicted

An uncontrolled six-week series in 11 older men improved two of six strength measures (Vittone 1997). A review reports that the six-month University of Washington trial found no strength or aerobic gain, though function held steady while placebo recipients declined (Hersch 2008). Net: no consistent functional benefit.

Magnitude: Not quantified in available studies. Neither report gives between-group effect sizes for strength or functional performance scores.

Well-Being and Libido in Men

Sixteen weeks of nightly [Nle27]GHRH(1-29), an analogue differing from sermorelin by one amino acid, improved general well-being and libido in men but not women after a placebo lead-in (Khorram 1997). Evidence is indirect (analogue) and single-blind.

Magnitude: Direction only: well-being and libido scores improved significantly in men compared with the placebo phase; the literature reports no outcome figure.

Skin Thickness

The same analogue trial measured thicker skin at four sites in both sexes after 16 weeks (Khorram 1997). Evidence is indirect, because the compound was an analogue of sermorelin, and skin thickness was measured with calipers rather than clinical skin outcomes.

Magnitude: Direction only: skin thickness increased significantly in men and women versus the placebo phase; the literature reports no outcome figure.

Sleep Quality ⚠️ Conflicted

Repeated GHRH injections deepen non-REM sleep after sleep deprivation (Schüssler 2006), indirect evidence by route and peptide. In older adults, self-rated sleep slightly worsened with nightly sermorelin but not with placebo, without a between-group test (Vitiello 2001). Net: chronic sermorelin does not improve sleep in older adults.

Magnitude: Pittsburgh Sleep Quality Index (PSQI, a validated sleep questionnaire; higher is worse) rose from 4.1 to 5.4 with sermorelin and from 4.5 to 4.6 with placebo; not compared between groups (Vitiello 2001).

Speculative 🟨

Restoring Youthful GH and IGF-1 Levels

Twice-daily sermorelin returned GH and IGF-1 in older men to young-adult levels (Corpas 1992), a consistently replicated effect. IGF-1 is an unvalidated surrogate: raising it has not been shown to improve health outcomes.

Immune Function

The [Nle27]GHRH(1-29) analogue increased B cells (antibody-producing white cells), T-cell activation markers and white-cell responses in older adults (Khorram 1997). These are unvalidated immune biomarkers; no infection or vaccine outcomes were measured.

Lifespan Extension

No human data link sermorelin to longer life. Animal evidence points the other way: mice lacking GHRH live longer (Sun 2013). The basis for any lifespan benefit is mechanistic only.

Benefit-Modifying Factors

  • Genetic polymorphisms: Loss-of-function mutations in the GHRHR gene abolish the GH response, as in the Brazilian Itabaianinha cohort (reviewed by Aguiar-Oliveira 2019). No common variants are known to predict response, and sermorelin’s breakdown does not involve CYP enzymes.
  • Baseline biomarkers: Trials enrolled older adults with low or low-normal IGF-1 (Vittone 1997); those already in the young-adult IGF-1 range have less room to rise. Obesity and high blood fats blunt GH release to GHRH (Cordido 1996).
  • Sex differences: Men gained lean mass, insulin sensitivity, well-being and libido while women did not (Khorram 1997). Women on oral estrogen had IGF-1 rises under 10%, versus about 30–40% in men and non-users (Vitiello 2001).
  • Pre-existing conditions: Sermorelin works only when the pituitary is intact, so pituitary tumors, surgery or radiation make it ineffective (Hersch 2008). Untreated hypothyroidism (underactive thyroid) reduces the response (Geref label; RxList sermorelin label).
  • Age: The older pituitary still responds to GHRH (Corpas 1992), but responses in people aged 65–97 were smaller than in young adults (Giustina 1992), so benefits may shrink at the oldest ages.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the adverse-event rates come from uncontrolled open-label pediatric trials and label summaries, not from placebo-controlled trials by more than one research group.

Medium 🟥 🟥

Poorer Self-Rated Sleep

In the University of Washington placebo-controlled trial, nightly sermorelin slightly worsened self-rated sleep while placebo did not (Vitiello 2001), and, per a review, deep sleep was not improved and may have been impaired (Hersch 2008). The proposed mechanism is a single large GH burst after injection followed by suppressed late-night GH. One user reported consistent loss of second-half REM sleep (Huberman Lab episode).

Magnitude: PSQI score rose by 1.3 points with sermorelin and by 0.1 points with placebo among 75 older adults; not compared between groups (Vitiello 2001).

Low 🟥

Anti-Sermorelin Antibodies

Many treated patients develop antibodies against sermorelin; positive tests often turn negative later, and no effect on growth or side-effect pattern was seen (Geref label). In a Venezuelan Geref cohort, antibodies appeared in about half of children who responded (Lanes 1994). Evidence is uncontrolled; long-term adult allergy risk is unknown.

Magnitude: 6 of 11 responding children (55%) tested antibody-positive at 12 months; no control group (Lanes 1994).

Injection-Site Reactions

Pain, swelling or redness where the drug is injected is the most common adverse event in the manufacturer’s (Serono) uncontrolled pediatric trial program (Geref label); the University of Washington group reported it as uncommon in adults (Vitiello 2001). Reactions are local, brief and rarely lead to stopping.

Magnitude: About 1 in 6 patients in Geref trials, with 3 of 350 stopping because of injection reactions; no control group (Geref label; summarized in the drug review Prakash 1999).

Unmasking of Hypothyroidism

Some children developed hypothyroidism needing thyroid replacement during uncontrolled Geref trials (Geref label). GH speeds conversion of thyroxine (T4, the main circulating thyroid hormone) to triiodothyronine (T3, its active form), which can change replacement needs (Hersch 2008). The label requires thyroid testing before and during treatment (RxList sermorelin label).

Magnitude: Hypothyroidism incidence of 6.5% during Geref therapy in pediatric trials; no control group (Geref label).

Flushing, Headache and Other Systemic Reactions

Beyond injection-site reactions, uncontrolled Geref trials recorded headache, flushing, dysphagia (difficulty swallowing), dizziness, hyperactivity, sleepiness and urticaria (hives) (Geref label). A drug review reports brief facial flushing as the most typical reaction to intravenous testing doses (Prakash 1999). These effects are short-lived.

Magnitude: Each occurred in less than 1% of patients receiving subcutaneous Geref; no control group (Geref label).

Blood Sugar and Insulin Changes ⚠️ Conflicted

Twice-daily sermorelin raised fasting glucose and insulin in short children (Kirk 1994), an uncontrolled series. Tesamorelin raised fasting insulin in adults with MCI (Baker 2012), indirect evidence. A randomized dosing trial in older men found fasting glucose unchanged (Corpas 1992). Net: small rises are possible with frequent dosing.

Magnitude: Direction only: rises appeared with twice-daily dosing in children and with tesamorelin, not with sermorelin in healthy older men; the literature reports no outcome figure for sermorelin.

Cancer Promotion Through Higher IGF-1

No study has measured cancer with sermorelin. Evidence is indirect (the body’s own IGF-1): pooled prospective and Mendelian randomization (MR, using inherited variants to test causation) data link higher IGF-1 to prostate cancer (Watts 2023); a UK Biobank cohort links it to breast, colorectal and thyroid cancer (Knuppel 2020).

Magnitude: Odds ratio (OR, the relative odds of disease) for prostate cancer of 1.09 (95% confidence interval, CI, the range likely to contain the true value: 1.07–1.11) per standard deviation (a typical spread around the average) higher IGF-1, and 1.07 (1.00–1.15) by MR; endogenous IGF-1, not sermorelin (Watts 2023).

Fluid Retention, Joint Pain and Carpal Tunnel Syndrome

These, including carpal tunnel syndrome (nerve compression at the wrist), are hallmark effects of excess GH in older adults; evidence for sermorelin is indirect. Nightly sermorelin produced very uncommon edema and joint pain (Vitiello 2001), but combined secretagogues or high doses could approach GH-like exposure.

Magnitude: With GH itself, a review reports edema in about 40%, joint pain in about 20% and carpal tunnel syndrome in about 10% of patients; no control group (Hersch 2008). With nightly sermorelin, edema and joint pain were “very uncommon”, with no rates given (Vitiello 2001).

Transient Rise in Blood Lipids

The only adverse effect in the 16-week [Nle27]GHRH(1-29) analogue trial was a temporary rise in blood lipids, which resolved by study end (Khorram 1997). Evidence is indirect because the compound was an analogue.

Magnitude: Not quantified in available studies. The trial report describes the event without lipid values or a placebo comparison.

Speculative 🟨

Direct Tumor Stimulation via GHRH Receptors

GHRH transformed normal prostate cells into tumor-forming cells (Muñoz-Moreno 2022) and sermorelin’s peptide stimulated neuroendocrine (hormone-producing) tumor cells (Stepień 2009). Basis is cell and animal data only.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic variants affecting sermorelin handling are known. Inherited cancer predisposition, such as BRCA1/2 (DNA-repair genes whose faulty versions raise breast and ovarian cancer risk), may raise the stakes of higher IGF-1, an inference from the IGF-1 cancer data (Watts 2023).
  • Baseline biomarkers: High-normal baseline IGF-1, prediabetic glucose or HbA1c (average blood sugar over three months), raised PSA, or abnormal thyroid tests increase the importance of the risks above (Geref label; Corpas 1992).
  • Sex differences: Earlier studies, cited by a later trial that itself found no sex difference (Schüssler 2006), reported that GHRH impairs sleep in women while promoting it in men. Men carry the prostate-specific concern; the IGF-1 association with breast cancer applies to women (Knuppel 2020).
  • Pre-existing conditions: Active or past cancer, diabetes or impaired glucose tolerance, untreated hypothyroidism and existing carpal tunnel syndrome raise risk. The Italian label (summary of product characteristics, SmPC) advises caution in epilepsy (Geref test SmPC).
  • Age: Older adults are more sensitive than younger ones to GH side effects, so GH-excess effects appear at lower exposures (Hersch 2008); background cancer risk also rises with age.

Key Interactions & Contraindications

Documented interactions:

  • Glucocorticoids (steroid anti-inflammatory drugs: prednisone, dexamethasone, hydrocortisone, inhaled budesonide or fluticasone): blunt the GH response, reducing efficacy (Geref label; Giustina 1990; Malerba 2005). Mitigation: response is judged by IGF-1 rather than dose.
  • Oral estrogen (estradiol tablets, conjugated estrogens): IGF-1 rose under 10% in women on oral estrogen, versus about 30% in non-users (Vitiello 2001). Mitigation: IGF-1 tracking; skin-applied (transdermal) estrogen bypasses the liver first-pass effect (liver processing before wider circulation) thought responsible.
  • Aromatase inhibitors and tamoxifen (estrogen-blocking drugs: anastrozole, letrozole, tamoxifen): smaller IGF-1 increases in men on sermorelin-containing regimens (Sigalos 2017). Mitigation: IGF-1 results are interpreted with this in mind.
  • Ghrelin-mimetic secretagogues (drugs mimicking the hunger hormone ghrelin: ipamorelin, ibutamoren, and the growth hormone-releasing peptides GHRP-2 and GHRP-6): act synergistically with GHRH on GH release (Veldhuis 2009), raising the chance of GH-excess effects. Mitigation: IGF-1 kept within the age-adjusted range.
  • Somatropin (recombinant GH): prior or concurrent GH therapy alters the response to sermorelin through feedback (Geref test SmPC), and combined use adds GH exposure. Mitigation: combined use is avoided; for testing, the label specifies 1–2 weeks off GH.
  • Somatostatin and its analogues (octreotide, lanreotide): suppress GH release, cancelling sermorelin’s effect (Geref test SmPC; Achermann 1999). Mitigation: sermorelin has no expected effect during such therapy.
  • Insulin and insulin-releasing drugs (insulin glargine, glipizide): listed as interfering with the GH response (Geref test SmPC); GH also opposes insulin action, which can raise glucose. Mitigation: closer glucose monitoring.
  • Cyclooxygenase inhibitors (anti-inflammatory painkillers: aspirin, indomethacin): may alter the GH response (Geref test SmPC). Mitigation: occasional over-the-counter aspirin is unlikely to matter; with regular use, IGF-1 is checked.
  • Antimuscarinic drugs (blockers of the nerve signal acetylcholine: atropine, scopolamine): may alter the GH response (Geref test SmPC). Mitigation: IGF-1 check with regular use.
  • Antithyroid drugs and thyroid hormone (propylthiouracil, methimazole, levothyroxine): thyroid status changes the response, and GH can change levothyroxine needs (Geref test SmPC; Geref label). Mitigation: thyroid-stimulating hormone (TSH) and free T4 testing before and during use.
  • Beta-1 blockers (heart-rate-lowering drugs: atenolol, metoprolol): atenolol increased the growth response to GHRH in a randomized trial (Cassorla 1995). Consequence: a stronger GH effect. Mitigation: IGF-1 monitoring.
  • Cholinesterase inhibitors (drugs that boost acetylcholine: pyridostigmine, donepezil): pyridostigmine enhanced the GH response to GHRH(1-29) in young and older adults (Giustina 1992). Consequence: higher GH exposure. Mitigation: IGF-1 monitoring.
  • Clonidine and levodopa (a blood-pressure drug and a Parkinson’s drug): listed as raising GH (Geref test SmPC); in a randomized trial, clonidine did not augment the GH response to GHRH(1-29) (Suri 1990). Consequence: distorted GH readings. Mitigation: IGF-1 interpreted with these drugs in mind.
  • Arginine supplements: a meta-analysis found that adding GHRH to arginine produced a larger GH release than arginine alone (Goli 2022). Consequence: additive GH exposure. Mitigation: arginine intake accounted for when titrating against IGF-1.
  • Carbohydrate-rich meals near dosing: high blood sugar and triglycerides blunt the response (Geref test SmPC), and lowering blood fats tripled the GH response to GHRH in obese adults (Cordido 1996). Mitigation: dosing at least 2 hours after eating.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • DPP-4 inhibitors (oral diabetes drugs: sitagliptin, linagliptin): inferred from DPP-4 being the main enzyme inactivating sermorelin (Frohman 1989); blocking it may prolong and amplify sermorelin’s GH effect. Mitigation: IGF-1 check after starting either drug.
  • Other GHRH analogues (tesamorelin, CJC-1295): inferred from shared GHRHR activation; additive GH exposure with GH-excess effects. Mitigation: combining GHRH analogues is avoided.
  • Testosterone therapy (testosterone cypionate, testosterone gel): inferred from testosterone’s conversion to estradiol amplifying GH pulses; may add to sermorelin’s GH effect. Mitigation: IGF-1 recheck after testosterone dose changes.

Populations who should avoid Sermorelin:

  • Pregnancy and breastfeeding: the Italian label states it must not be used (Geref test SmPC); US Pregnancy Category C (Geref label; RxList sermorelin label).
  • Known hypersensitivity to sermorelin or inactive ingredients such as mannitol (US label contraindication) (Geref label; RxList sermorelin label).
  • GH deficiency caused by an intracranial lesion, such as a brain tumor (not recommended in the US label) (Geref label; RxList sermorelin label).
  • Active cancer: inferred from the growth-promoting effects of IGF-1 and GHRH on tumors; no human data (Watts 2023; Muñoz-Moreno 2022).
  • Diabetes, defined by HbA1c at or above the 6.5% diagnostic threshold of the American Diabetes Association (ADA), whose members earn no sermorelin revenue: inferred from GH’s anti-insulin action; no human data with sermorelin (ADA 2026).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • IGF-1-guided dosing: Prevents GH-excess effects and limits IGF-1 cancer exposure. IGF-1 is kept within the age- and sex-adjusted reference range, the Endocrine Society’s GH-therapy target (members prescribe GH) (Molitch 2011); the dose is reduced if IGF-1 exceeds its upper limit.
  • Thyroid testing: Mitigates unmasked hypothyroidism. TSH and free T4 are checked before starting and periodically during treatment, as the label requires (Geref label; RxList sermorelin label), with replacement when indicated.
  • Glucose surveillance: Mitigates glucose and insulin rises. Fasting glucose and HbA1c at baseline and every 3–6 months; use is paused if fasting glucose reaches 126 mg/dL or HbA1c 6.5%, the ADA diabetes thresholds (members earn no sermorelin revenue) (ADA 2026).
  • Cancer screening before and during use: Mitigates cancer-promotion concerns. Age-appropriate screening is completed first; in men, PSA is tracked at baseline and every 6–12 months, with use stopped if it rises persistently.
  • Injection technique and site rotation: Reduces injection-site reactions. Injection sites are periodically rotated, as the label recommends (Geref label; RxList sermorelin label), with sterile single-use needles.
  • No secretagogue combinations without monitoring: Prevents GH-excess fluid retention, joint pain and nerve compression. IGF-1 is rechecked four to six weeks after adding any ghrelin mimetic or other GHRH analogue.
  • Sleep tracking: Detects sleep disruption. Sleep diary or wearable data are compared for two weeks before and after starting; the dose is stopped or moved earlier if deep or REM sleep falls.
  • Pharmacy-grade sourcing: Reduces contamination and wrong-dose risk. Licensed compounding pharmacies providing potency and sterility testing are used instead of “research use only” products.

Therapeutic Protocol

Timing, cycling and titration steps below follow common practice unless cited.

  • Trial regimen (older adults): About 1 mg (14 µg/kg) once nightly under the skin for 5–6 months, used by the University of Washington group (Vitiello 2001; Vitiello 2006).
  • Twice-daily regimen: 1 mg twice daily restored IGF-1 to young-adult levels in older men (0.5 mg did not significantly) (Corpas 1992); 2 mg once nightly for six weeks did not raise IGF-1 (Vittone 1997).
  • Clinic regimen: 200–3,000 µg at bedtime, five days on and two off, often compounded with other peptides, as used by Dr. Craig Koniver (Huberman Lab episode).
  • Label regimen (children): 30 µg/kg once daily at bedtime for GH deficiency (Geref label); adult longevity use was popularized by advocates such as Richard Walker (Walker 2006).
  • Competing approaches: Recombinant GH replaces the hormone directly; ghrelin mimetics such as ibutamoren act through a different receptor; sermorelin relies on the patient’s own pituitary. None has outcome data supporting use in healthy ageing (Hersch 2008).
  • Best time of day: Bedtime injection on an empty stomach, aligning the GH burst with the natural night-time peak; high blood sugar blunts the response (Geref test SmPC).
  • Half-life: 11–12 minutes (Geref label); the GH rise lasts about 2 hours after each injection (Khorram 1997), while IGF-1 stays raised between doses.
  • Single versus split dose: Twice-daily dosing raised IGF-1 more than once-nightly dosing (Corpas 1992; Vittone 1997), but doubles injections and may raise glucose effects; most clinics use one nightly dose.
  • Genetic polymorphisms: No variants guide dose; GHRHR loss-of-function mutations make sermorelin ineffective (reviewed by Aguiar-Oliveira 2019), and no CYP pharmacogenetics apply.
  • Sex differences: Women on oral estrogen show much smaller IGF-1 rises (Vitiello 2001) and may need IGF-1-guided dose adjustment; men showed broader responses in the analogue trial (Khorram 1997).
  • Age: Responses persist in older adults but shrink with advanced age (Giustina 1992); lower starting doses are used in the oldest users, who are more sensitive to GH side effects (Hersch 2008).
  • Baseline biomarkers: Low or low-normal IGF-1 defines the population studied (Vittone 1997); a baseline already in the upper reference range offers little room and more risk.
  • Pre-existing conditions: Obesity blunts GH release (Cordido 1996); pituitary damage abolishes the response (Hersch 2008); untreated hypothyroidism reduces it (Geref label; RxList sermorelin label).

Discontinuation & Cycling

  • Lifelong or short-term: Adult trials lasted two weeks to six months, and no data exist beyond that; clinic use is often open-ended. Whether sermorelin is a course or a lifelong therapy is unresolved (Hersch 2008).
  • Withdrawal effects: None reported in adults. In children, growth slowed below baseline for three months after stopping, then returned to pre-treatment rates (Kirk 1994).
  • Tapering: Not studied; trials stopped it abruptly. Evidence on pituitary suppression conflicts: GH responses to GHRH were preserved or enhanced in one trial (Neyzi 1993) but fell over 12 months of twice-daily dosing in another (Kirk 1994).
  • Cycling: A five-days-on, two-off schedule is used in clinics (Huberman Lab episode). IGF-1 drifted back toward baseline by week 16 despite continued dosing (Khorram 1997); whether cycling prevents this is untested.

Sourcing and Quality

  • No approved product: FDA withdrew Geref’s approvals in 2009, finding the withdrawal was not for safety (FDA Federal Register notice); Drugs.com lists no marketed US product (Drugs.com Geref monograph). Supply comes from compounding pharmacies, whose products the FDA does not approve (FDA compounding Q&A).
  • Gray-market peptides: “Research use only” vials sold online have uncertain identity, dose and sterility, according to a narrative review (Dominikowski 2026).
  • What to look for: A state-licensed pharmacy filling a named prescription, with a certificate of analysis showing identity, potency, sterility and endotoxin (bacterial toxin) testing; accreditation by a compounding accreditation body adds assurance.
  • Formulation: Freeze-dried sermorelin acetate is stored refrigerated and mixed with sterile diluent before injection, as the original label describes (RxList sermorelin label). Compounded multi-dose vials rely on preservatives and stated beyond-use dates (the pharmacy-assigned date after which the mixed product should no longer be used).
  • Oral and nasal forms: Some compounders sell 1,000 µg dissolving tablets (Empower Pharmacy product page); oral absorption is unestablished, and nasal bioavailability is only 3–5% (Wilton 1993).
  • Compounding pharmacies: Large US 503A compounders (state-licensed pharmacies preparing drugs for individual prescriptions), such as Empower Pharmacy, list sermorelin products by prescription (Empower Pharmacy product page); naming one is not an endorsement or a verification of its quality.

Practical Considerations

  • Time to effect: GH rises within minutes and IGF-1 within two weeks (Khorram 1997); body-composition changes were reported at five to six months (Vitiello 2001) and cognitive changes at six months (Vitiello 2006).
  • Common pitfalls: Injecting after carbohydrate-rich meals, judging success by flushing or tingling, and buying gray-market peptides (Huberman Lab episode); combining several secretagogues without IGF-1 checks; relying on oral forms; expecting strength gains without training (Hersch 2008).
  • Regulatory status: Geref’s US approvals, for pediatric treatment and diagnostic testing, were withdrawn in 2009; prescribing it for ageing is off-label use of a compounded drug (FDA Federal Register notice; FDA compounding Q&A).
  • Structural incentives: Without patent protection or a manufacturer, no sponsor funds outcome trials. Insurers cover neither sermorelin nor costlier GH for ageing, so payer incentives bias neither guidelines nor funding; evidence comes mostly from small academic studies and clinic advocacy (Walker 2006).
  • Access: Requires a prescriber and a compounding pharmacy; availability outside the US depends on national rules for compounded peptides.

Interaction with Foundational Habits

  • Sleep: Blunting at worst, no benefit at best. GH is released mainly in early deep sleep, yet nightly sermorelin slightly worsened self-rated sleep in older adults (Vitiello 2001); earlier studies cited by a later trial, which saw no sex difference, found GHRH impairs sleep in women (Schüssler 2006). Sleep tracking when starting helps detect disruption.
  • Nutrition: Potentiating when fasted, blunting when fed. High blood sugar and blood fats reduce the GH response (Geref test SmPC; Cordido 1996), so protocols place injections at least two hours after the last meal; adequate protein supports any lean-mass gain.
  • Exercise: Independent effects. A review of the University of Washington trial reports that exercise training improved fitness while sermorelin did not add to it, suggesting different mechanisms (Hersch 2008). Resistance and aerobic training remain the main drivers of strength and function.
  • Stress management: Stress hormones blunt the response. Lowering cortisol enhanced the GH response to GHRH in healthy men (Dinan 1994), and glucocorticoids suppress it (Giustina 1990). Chronic stress may therefore reduce sermorelin’s effect.

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes eligibility and a reference point: IGF-1 to confirm low or low-normal levels, fasting glucose and HbA1c to exclude diabetes, thyroid tests because the label requires them, a lipid panel, PSA in men, and a body-composition scan if lean mass or fat is a goal. Age-appropriate cancer screening is usually brought up to date first.

Ongoing monitoring follows a cadence of IGF-1 at 4–6 weeks and after any dose change, then every 3–6 months; fasting glucose, HbA1c and thyroid tests every 3–6 months; lipids and PSA every 6–12 months; and a repeat body-composition scan at 6 months. Success means IGF-1 within the age-adjusted range, stable glucose and thyroid values, and measurable change in the goals set at baseline, without worse sleep.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
IGF-1 Within the age- and sex-adjusted reference range, below its upper limit (Endocrine Society target for GH therapy) Expected to change; safety check for GH excess Target from Molitch 2011; the Endocrine Society’s members prescribe GH therapy. Conventional reference range is age- and assay-specific (laboratory-reported). A morning draw is typical; IGF-1 is stable through the day.
Fasting glucose Below 100 mg/dL (ADA normal fasting glucose) Safety check; rises stop or change use Source: ADA 2026; members of the American Diabetes Association earn no revenue from sermorelin. Conventional reference range 70–99 mg/dL. Requires an 8-hour fast.
HbA1c Below 5.7% (ADA normal range) Safety check; rises stop or change use Source: ADA 2026; members of the American Diabetes Association earn no revenue from sermorelin. Conventional reference range 4.0–5.6%. Usually paired with fasting glucose.
TSH and free T4 TSH 0.4–4.0 mIU/L; free T4 0.8–1.8 ng/dL (standard reference range) Safety check for unmasked hypothyroidism Required before and during therapy by the US label (Geref label; RxList sermorelin label). Morning sample; biotin supplements can distort results.
Fasting triglycerides and LDL cholesterol No established target; track change from the individual’s own baseline Safety check for lipid rises LDL: low-density lipoprotein, the main artery-clogging cholesterol. Transient rises reported with an analogue (Khorram 1997). Requires a 9–12-hour fast.
PSA (men) No established target; track change from the individual’s own baseline Safety check; persistent rise stops use Concern based on IGF-1 and prostate cancer (Watts 2023). The common 4.0 ng/mL value is a screening cutoff, not a reference range. Ejaculation or cycling within 48 hours before testing can raise PSA.
Lean mass and fat mass by DEXA No established target; track change from the individual’s own baseline Expected to change DEXA: dual-energy X-ray absorptiometry, a body-composition scan. Body-composition effects reported by Vitiello 2001. Comparable results need the same device and a fasted, well-hydrated state.

Qualitative markers:

  • Sleep quality, including time awake at night and dream recall, by diary or wearable
  • Energy and exercise recovery
  • Joint stiffness, hand numbness or tingling, and ankle swelling as early signs of GH excess
  • Injection-site redness, swelling or itching
  • Mental sharpness and processing speed in daily tasks

Emerging Research

  • No active sermorelin trials: A search of ClinicalTrials.gov in October 2026 (ClinicalTrials.gov sermorelin search) found no recruiting or active sermorelin studies; the adult evidence still rests on trials from the 1990s and 2000s (Hersch 2008).
  • Tesamorelin plus exercise in older adults with HIV (human immunodeficiency virus): NCT06554717, Phase 2, 100 participants, primary endpoint repeated chair-stand time, recruiting, completion December 2028. A positive result would raise the case for GHRH-class drugs in physical function; a null result would strengthen the view that they do not improve function.
  • Tesamorelin for cognition in ageing adults with HIV: NCT02572323, completed 2023; posted results show neurocognitive z-score (standardized score) changes of +0.15 versus +0.10 in the deferred group, despite IGF-1 rising 53% versus 5%. This weakens the cognitive signal for GHRH-class drugs, though it did not test sermorelin.
  • Low-dose tesamorelin pilot in MCI: NCT02553603, completed 2019, 22 participants; published results found no significant change in cognition, body composition or sleep (Stewart 2026).
  • IGF-1 and cancer causation: Mendelian randomization now supports a causal role for IGF-1 in prostate cancer (Watts 2023); similar analyses for other cancers could firm up or ease the main long-term concern about any IGF-1-raising therapy.
  • GH signaling and longevity: GHRH-deficient mice live longer (Sun 2013) and humans with GHRHR mutations show normal lifespan with less cancer, per a review (Aguiar-Oliveira 2019); work clarifying whether these findings apply to restoring GH in later life could weaken or reframe the rationale.
  • Long-term outcome trials: Researchers call for trials on falls, fractures, function and vascular disease before any role in ageing is established (Hersch 2008); none are registered for sermorelin.

Conclusion

Sermorelin is a short, lab-made version of the brain signal that tells the pituitary gland to release growth hormone. It reliably raises the body’s own growth hormone and its main downstream hormone in older adults, and because the body’s natural brakes stay in place, it is often presented as a gentler alternative to taking growth hormone itself.

Whether that hormonal change translates into better health is much less clear. The most promising finding, better performance on some thinking tasks in healthy older adults, comes from one research group and has not been confirmed with sermorelin. Effects on body composition, strength, well-being and skin rest on small, short or indirect studies, and sleep did not improve. No study has looked at lifespan, and animal and human genetic evidence suggests lower growth hormone activity may favor longer life.

The most common harms are local injection reactions, with frequent antibodies of unclear significance and occasional thyroid changes. Longer-term questions about blood sugar and cancer remain open, because higher levels of the downstream hormone are linked to some cancers and no long-term safety data exist.

The evidence base is small and dated, with the children’s trials run by the original manufacturer, and current adult use is promoted mainly by clinics and custom-mixing pharmacies that profit from it. For health-focused adults, sermorelin remains an experimental tool with a plausible rationale, a real hormonal effect and largely unproven benefits.

Top - Benefits - Risks - Protocol